Pharmaceutical Companies

This arrangement strengthens an existing partnership between the two pharmaceutical giants, who already collaborate on manufacturing the mpox vaccine.

This latest commitment builds on a previous 7 billion yen (USD44 million) investment between 2022 and 2025, which funded automated device-sorting machines, enhancements to the quality testing lab, a new factory building, and an additional packaging line.

The company plans to execute this investment through two primary channels: expanding existing facilities and forging partnerships with local manufacturers.

By combining its global operations with Biocare’s established commercial presence across the United States, the company aims to reach a wider customer base and strengthen its market position.

The company also secured additional preferential participation in future exit proceeds, though these returns depend on Lone Star first recovering its initial equity investment.

Alfasigma will pay GSK USD 300 million upfront, with an additional USD 100 million due upon US Food and Drug Administration (FDA) approval.

Rather than consolidating operations through plant closures, EMS intends to retain Medley’s existing facilities and invest in future expansion.

The self-administered nasal spray therapy bridges the gap between oral and intravenous diuretic treatments, offering patients an outpatient option for managing their condition.

Pfizer secured marketing rights to the GLP-1 compound ecnoglutide through a partnership with Hangzhou-based Sciwind Biosciences announced last month.

The LEED Gold-certified facility features flexible laboratory configurations and advanced mechanical and utility systems, enabling researchers to conduct intricate scientific research.